Focus
Vincamine
Vincamine is a plant alkaloid studied in dementia, not as an acute focus aid for healthy athletes.
How it counts: Not part of the score
We show it on the label and count it as disclosed, but it never affects Dose, any sub-score or the grade. The basis below explains why.
- Clinical dose
- No established clinical dose
- Safety ceiling
- —
- Evidence
- weak
- Category
- Focus
Evidence summary
Research confidence: low
No pre-workout reference dose. The best located placebo-controlled human trial used 30 mg twice daily for 12 weeks in adults aged 50–85 with degenerative or vascular dementia. That therapeutic population and chronic 60 mg/day regimen do not establish efficacy for a healthy athlete taking 10 mg acutely before exercise. No exercise-performance or healthy-adult acute-focus trial was found.
Research sources
- Therapeutic efficacy of vincamine in dementia (Fischhof et al., Neuropsychobiology 1996)(opens in new window)
- Vincamine, PubChem CID 15376(opens in new window)
Identifies vincamine as a monoterpenoid indole alkaloid obtained from Vinca minor and distinguishes the compound from its synthetic derivative vinpocetine.
- New Dietary Ingredient Notifications 1995 to the Present (U.S. FDA)(opens in new window)
Lists two General Nutrition Corporation vincamine NDI submissions from 1999 and 2000; listing records the notifications and is not FDA approval or proof of efficacy.